Comparative Pharmacology
Head-to-head clinical analysis: FLURAZEPAM HYDROCHLORIDE versus MENRIUM 10 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLURAZEPAM HYDROCHLORIDE versus MENRIUM 10 4.
FLURAZEPAM HYDROCHLORIDE vs MENRIUM 10-4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA by increasing the frequency of chloride channel opening.
Mennium 10-4 is a combination of chlordiazepoxide, a benzodiazepine that enhances GABA-A receptor activity, and clidinium, an antimuscarinic that blocks muscarinic acetylcholine receptors.
15-30 mg orally at bedtime as a single dose for insomnia; maximum dose 30 mg/day.
Adults: 1 tablet (chlordiazepoxide 10 mg / clidinium 4 mg) orally 3 to 4 times daily before meals and at bedtime. Max: 4 tablets per day.
None Documented
None Documented
Terminal elimination half-life: 40-114 hours (mean 74 hours); accumulates extensively with repeated dosing, leading to prolonged sedation.
Chlordiazepoxide: 5-30 h (mean 20 h); clidinium: 10-20 h. Steady-state reached in 5-7 days.
Renal: 90% (as metabolites, <1% unchanged); Fecal: <10%; Biliary excretion minimal.
Renal (60% as unchanged chlordiazepoxide, 15% as conjugated metabolites; 5% biliary/fecal as metabolites)
Category D/X
Category C
Benzodiazepine
Benzodiazepine/Estrogen Combination